Advertisement

Targeted Therapy and Immunotherapy in Melanoma

Published:October 27, 2022DOI:https://doi.org/10.1016/j.det.2022.07.007

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Dermatologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Saginala K.
        • Barsouk A.
        • Aluru J.S.
        • et al.
        Epidemiology of Melanoma.
        Med Sci (Basel). 2021; 9: 63
        • National Comprehensive Cancer Network
        Melanoma: Cutaneous (version 1.2022).
        (Available at:) (Accessed December 5, 2021)
        • Cancer Institute National
        Melanoma of the Skin-Cancer Stat Facts.
        (Available online:) (Accessed on December 3, 2021)
        • Chapman P.B.
        • Hauschild A.
        • Robert C.
        • et al.
        Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
        N Engl J Med. 2011; 364: 2507-2516
        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer Statistics.
        CA Cancer J Clin. 2020; 70: 7-30
        • Patel H.
        • Yacoub N.
        • Mishra R.
        • et al.
        Current Advances in the Treatment of BRAF-Mutant Melanoma.
        Cancers. 2020; 12: 482
        • LoRusso P.M.
        • Schalper K.
        • Sosman J.
        Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma.
        Pigment Cell Melanoma Res. 2020; 33: 390-402
        • McArthur G.A.
        • Chapman P.B.
        • Robert C.
        • et al.
        Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM- 3): Extended follow-up of a phase 3, randomised, open-label study.
        Lancet Oncol. 2014; 15: 323-332
        • Chapman P.B.
        • Robert C.
        • Larkin J.
        • et al.
        Vemurafenib in patients with BRAFV600 mutation- positive metastatic melanoma: Final overall sur- vival results of the randomized BRIM-3 study.
        Ann Oncol. 2017; 28: 2581-2587
        • Luke J.J.
        Comprehensive clinical trial data summation for BRAF-MEK inhibition and checkpoint immunotherapy in metastatic melanoma.
        Oncologist. 2019; 24: e1197-e1211
        • Hauschild A.
        • Grob J.J.
        • Demidov L.V.
        • et al.
        Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial.
        Lancet. 2012; 380: 358-365
        • Dummer R.
        • Ascierto P.A.
        • Gogas H.J.
        • et al.
        Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): A multicentre, open-label, randomised, phase 3 trial.
        Lancet Oncol. 2018; 19: 1315-1327
        • Anforth R.
        • Menzies A.
        • Byth K.
        • et al.
        Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.
        J Am Acad Dermatol. 2015; 72: 809-815
        • Sun J.
        • Zager J.S.
        • Eroglu Z.
        Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy.
        OncoTargets Ther. 2018; 11: 9081
        • Manzano J.L.
        • Layos L.
        • Buges C.
        • et al.
        Resistant mechanisms to BRAF inhibitors in melanoma.
        Ann Transl Med. 2016; 4: 237
        • Hoffner B.
        • Benchich K.
        Trametinib: a targeted therapy in metastatic melanoma.
        J Adv Pract Oncol. 2018; 9: 741-745
        • Flaherty K.T.
        • Robert C.
        • Hersey P.
        • et al.
        Improved survival with MEK inhibition in BRAF-mutated melanoma.
        N Engl J Med. 2012; 367: 107-114
        • Schadendorf D.
        • Flaherty K.T.
        • Hersey P.
        • et al.
        Overall survival (OS) update on METRIC (NCT01245062), a randomized phase 3 study to assess efficacy of trametinib (T) compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutation-positive (+) advanced or metastatic melanoma (MM).
        Pigment Cell Melanoma Res. 2013; 26: 997A
        • Robert C.
        • Flaherty K.
        • Nathan P.
        • et al.
        Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.
        Eur J Cancer. 2019; 109: 61-69
        • Dummer R.
        • Schadendorf D.
        • Ascierto P.A.
        • et al.
        Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicenter, open-label, randomsied, phase 3 trial.
        Lancet Oncol. 2017; 18: 435-445
        • Larkin J.
        • Ascierto P.A.
        • Dréno B.
        • et al.
        Combined vemurafenib and cobimetenib in BRAF-mutated melanoma.
        N Engl J Med. 2014; 371: 1867-1876
        • Ascierto P.A.
        • McArthur G.A.
        • Dréno B.
        • et al.
        Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM):Updated efficacy results from a randomised, double-blind, phase 3 trial.
        Lancet Oncol. 2016; 17: 1248-1260
        • Dréno B.
        • Ascierto P.A.
        • McArthur G.A.
        • et al.
        Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive metastatic melanoma: Analysis from the 4-year extended follow-up of the phase 3 coBRIM study.
        J Clin Oncol. 2018; 36: 9522A
        • Long G.V.
        • Stroyakovskiy D.
        • Gogas H.
        • et al.
        Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
        N Engl J Med. 2014; 71: 1877-1888
        • Long G.V.
        • Stroyakovskiy D.
        • Gogas H.
        • et al.
        Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial.
        Lancet. 2015; 386: 444-451
        • Long G.V.
        • Flaherty K.T.
        • Stroyakovskiy D.
        • et al.
        Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/k-mutant melanoma: Long-term survival and safety analysis of a phase 3 study.
        Ann Oncol. 2017; 28: 1631-1639
        • Robert C.
        • Karaszewska B.
        • Schachter J.
        • et al.
        Improved overall survival in melanoma with combined dabrafenib and trametinib.
        N Engl J Med. 2015; 372: 30-39
        • Robert C.
        • Karaszewska B.
        • Schachter J.
        • et al.
        Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/k-mutant cutaneous melanoma.
        Ann Oncol. 2016; 27: LBA40A
        • Dummer R.
        • Ascierto P.A.
        • Gogas H.J.
        • et al.
        Results of COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in BRAF-mutant melanoma.
        Oral presentation Annu Soc Melanoma Res Meet. 2016;
        • Dummer R.
        • Ascierto P.A.
        • Gogas H.J.
        • et al.
        Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial.
        Lancet Oncol. 2018; 19: 603-615
        • Dummer R.
        • Ascierto P.A.
        • Gogas H.
        • et al.
        Results of COLUMBUS part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma.
        Ann Oncol. 2017; 28: 1215OA
        • Sanlorenzo M.
        • Choudhry A.
        • Vujic I.
        • et al.
        Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
        J Am Acad Dermatol. 2014; 71: 1102-1109
        • Peng L.
        • Wang Y.
        • Hong Y.
        • et al.
        Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: A meta-analysis.
        Oncotarget. 2017; 8: 83280-83291
        • Passarelli A.
        • Mannavola F.
        • Stucci L.S.
        • et al.
        Immune system and melanoma biology: a balance between immunosurveillance and immune escape.
        Oncotarget. 2017; 8: 106132-106142
        • Onitilo A.A.
        • Wittig J.A.
        Principles of immunotherapy in melanoma.
        Surg Clin North Am. 2020; 100: 161-173
        • Hodi F.S.
        • O'Day S.J.
        • McDermott D.F.
        • et al.
        Improved survival with ipilimumab in patients with metastatic melanoma.
        N Engl J Med. 2010; 363: 711-723
        • Robert C.
        • Thomas L.
        • Bondarenko I.
        • et al.
        Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
        N Engl J Med. 2011; 364: 2517-2526
        • Robert C.
        • Long G.V.
        • Brady B.
        • et al.
        Nivolumab in previously untreated melanoma without BRAF mutation.
        N Engl J Med. 2015; 372: 320-330
        • Weber J.S.
        • D'Angelo S.P.
        • Minor D.
        • et al.
        Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial.
        Lancet Oncol. 2015; 16: 375-384
        • Weber J.
        • Minor D.
        • D'Angelo S.
        • et al.
        Overall survival in patients with advanced melanoma who received nivolumab vs investigator's choice chemotherapy in the phase 3 CheckMate 037 trial.
        Oral presentation Annu Soc Melanoma Res Meet. 2016;
        • Robert C.
        • Schachter J.
        • Long G.V.
        • et al.
        Pembrolizumab versus ipilimumab in advanced melanoma.
        N Engl J Med. 2015; 372: 2521-2532
        • Schachter J.
        • Ribas A.
        • Long G.V.
        • et al.
        Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
        Lancet. 2017; 390: 1853-1862
        • Long G.V.
        • Schachter J.
        • Ribas A.
        • et al.
        4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.
        J Clin Oncol. 2018; 36: 9503A
        • Keilholz U.
        • Ascierto P.A.
        • Dummer R.
        • et al.
        ESMO Consensus Conference Recommendations on the Management of Metastatic Melanoma: Under the Auspices of the ESMO Guidelines Committee.
        Ann Oncol. 2020; 31: 1435-1448
        • Robert C.
        • Ribas A.
        • Hamid O.
        • et al.
        Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma.
        J Clin Oncol. 2018; 36: 1668-1674
        • Jansen Y.J.L.
        • Rozeman E.A.
        • Mason R.
        • et al.
        Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: Clinical outcomes in advanced melanoma.
        Ann Oncol. 2019; 30: 1154-1161
        • Postow M.A.
        • Chesney J.
        • Pavlick A.C.
        • et al.
        Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
        N Engl J Med. 2015; 372: 2006-2017
        • Larkin J.
        • Chiarion-Sileni V.
        • Gonzalez R.
        • et al.
        Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.
        N Engl J Med. 2015; 373: 23-34
        • Wolchok J.D.
        • Chiarion-Sileni V.
        • Gonzalez R.
        • et al.
        Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).
        J Clin Oncol. 2016; 34: 9505A
        • Wolchok J.D.
        • Chiarion-Sileni V.
        • Gonzalez R.
        • et al.
        Overall survival with combined nivolumab and ipilimumab in advanced melanoma.
        N Engl J Med. 2017; 377: 1345-1356
        • Hodi F.S.
        • Chiarion-Sileni V.
        • Gonzalez R.
        • et al.
        Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multi- centre, randomised, phase 3 trial.
        Lancet Oncol. 2018; 19: 1480-1492
        • Larkin J.
        • Chiarion-Sileni V.
        • Gonzalez R.
        • et al.
        Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.
        N Engl J Med. 2019; 381: 1535-1546
        • National Comprehensive Cancer Network
        Management of Immunotherapy-Related Toxicities (version 4.2021).
        (Available at:) (Accessed December 5, 2021)
        • Simonsen A.B.
        • Kaae J.
        • Ellebaek E.
        • et al.
        Cutaneous adverse reactions to anti-PD-1 treatment-a systematic review.
        J Am Acad Dermatol. 2020; 83: 1415-1424
        • Owen C.N.
        • Bai X.
        • Quah T.
        • et al.
        Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
        Ann Oncol. 2021; 32: 917-925
        • Puzanov I.
        • Diab A.
        • Abdallah K.
        • et al.
        Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
        J Immunother Cancer. 2017; 5: 95
        • Hussaini S.
        • Chehade R.
        • Boldt R.G.
        • et al.
        Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors—A systematic review and meta-analysis.
        Cancer Treat Rev. 2020; 92: 102134
        • Luther C.
        • Swami U.
        • Zhang J.
        • et al.
        Advanced stage melanoma therapies: detailing the present and exploring the future.
        Crit Rev Oncol Hematol. 2019; 133: 99-111
        • Andtbacka R.H.
        • Kaufman H.L.
        • Collichio F.
        • et al.
        Talimogene laherparepvec improves durable response rate in patients with advanced melanoma.
        J Clin Oncol. 2015; 33: 2780-2788
        • Andtbacka R.H.
        • Ross M.
        • Puzanov I.
        • et al.
        Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial.
        Ann Surg Oncol. 2016; 23: 4169-4177
        • Chesney J.
        • Puzanov I.
        • Collichio F.
        • et al.
        Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
        J Clin Oncol. 2017; 36: 9509
        • Ribas A.
        • Chesney J.
        • Long G.V.
        • et al.
        1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL).
        Ann Oncol. 2021; 32: S868-S869
        • Byers B.
        • Temple-Oberle C.F.
        • McKinnon J.G.
        • et al.
        Treatment of in transit melanoma with intra-lesional interleukin-2: A systematic review.
        Can J Plast Surg. 2013; 21: 142
        • Damian D.L.
        • Saw R.P.
        • Thompson J.F.
        Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma.
        J Surg Oncol. 2014; 109: 308-313
        • Mora A.N.
        • Karia P.S.
        • Nguyen B.M.
        A quantitative systemic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance.
        J Am Acad Dermatol. 2015; 73: 205-212
        • Scarfì F.
        • Patrizi A.
        • Veronesi G.
        • et al.
        The role of topical imiquimod in melanoma cutaneous metastases: a critical review of the literature.
        Dermatol Ther. 2020; 1: e14165
        • Ferrucci P.F.
        • Di Giacomo A.M.
        • Del Vecchio M.
        • et al.
        Keynote-022 Part 3: A Randomized, Double-Blind, Phase 2 Study of Pembrolizumab, Dabrafenib, and Trametinib in BRAF-mutant Melanoma.
        J Immunother Cancer. 2020; 8: e001806
        • Ascierto P.A.
        • Ferrucci P.F.
        • Fisher R.
        • et al.
        Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
        Nat Med. 2019; 25: 941-946
        • Gutzmer R.
        • Stroyakovskiy D.
        • Gogas H.
        • et al.
        Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): Primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet. 2020; 395: 1835-1844
        • Eggermont A.M.M.
        • Chiarion-Sileni V.
        • Grob J.-J.
        • et al.
        Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy.
        N Engl J Med. 2016; 375: 1845-1855
        • Weber J.
        • Mandala M.
        • Del Vecchio M.
        • et al.
        Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.
        N Engl J Med. 2017; 377: 1824-1835
        • Eggermont A.M.M.
        • Blank C.U.
        • Mandala M.
        • et al.
        Adjuvant pembrolizumab versus placebo in resected stage III melanoma.
        N Engl J Med. 2018; 378: 1789-1801
        • Long G.V.
        • Hauschild A.
        • Santinami M.
        • et al.
        Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma.
        N Engl J Med. 2017; 377: 1813-1823
        • Maio M.
        • Lewis K.
        • Demidov L.
        • et al.
        Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
        Lancet Oncol. 2018; 19: 510-520
        • Amaria R.N.
        • Prieto P.A.
        • Tetzlaff M.T.
        • et al.
        Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
        Lancet Oncol. 2018; 19: 181-193
        • Amaria R.N.
        • Reddy S.M.
        • Tawbi H.A.
        • et al.
        Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
        Nat Med. 2018; 24: 1649-1654
        • Rozeman E.A.
        • Reijers I.L.
        • Hoefsmit E.P.
        • et al.
        Twenty-Four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma.
        J Clin Oncol. 2020; 38: 10015
        • Gopalakrishnan V.
        • Spencer C.N.
        • Nezi L.
        • et al.
        Gut microbiome modulates response to anti -PD-1 immunotherapy in melanoma patients.
        Science. 2018; 359: 97-103
        • Larkin J.
        • Minor D.
        • D’Angelo S.
        • et al.
        Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial.
        J Clin Oncol. 2018; 36: 383-390
        • Carlino M.S.
        • Long G.V.
        • Schadendorf D.
        • et al.
        Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: a randomised clinical trial.
        Eur J Cancer. 2018; 101: 236-243
        • Bajor D.L.
        • Mick R.
        • Riese M.J.
        • et al.
        Abstract CT137: Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma.
        Cancer Res. 2015; 75: CT137
        • Segal N.H.
        • Logan T.F.
        • Hodi F.S.
        • et al.
        Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody.
        Clin Cancer Res. 2017; 23: 1929-1936
        • Prendergast G.C.
        • Malachowski W.P.
        • DuHadaway J.B.
        • et al.
        Discovery of IDO1 Inhibitors: From Bench to Bedside.
        Cancer Res. 2017; 77: 6795-6811
        • Zakharia Y.
        • McWilliams R.
        • Shaheen M.
        • et al.
        Interim analysis of the phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma. [AACR abstract CT117].
        Cancer Res. 2017; 77: CT117